TPST Live signaler | Maksimer profitt med Getagraph.com

SELG 105111 min ago

@ $4.10

Utstedt: 14 feb 2024 @ 15:30

Avkastning: -13.66%

Forrige signal: feb 13 - 15:30

Forrige signal: Kjøp

Avkastning: -0.93 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	402 127
Gjennomsnittsvolum	979 955
Markedsverdi	78.65M
EPS	$0 ( 2024-03-27 )
Neste inntjeningsdato	( $-0.440 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.850
ATR14	$0.0120 (0.34%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-03	Brady Stephen R	Buy	250 000	Employee Stock Option (right to buy)
2024-01-03	Whiting Samuel	Buy	100 000	Employee Stock Option (right to buy)
2024-01-03	Trojanowski Justin	Buy	26 500	Employee Stock Option (right to buy)
2024-01-03	Maestas Nicholas	Buy	40 000	Employee Stock Option (right to buy)
2023-10-11	Brady Stephen R	Buy	725 000	Employee Stock Option (right to buy)

INSIDER POWER
99.69
Last 85 transactions
Buy: 12 322 880 \| Sell: 50 340

Volum Korrelasjon

Lang: 0.01 (neutral)

Kort: -0.68 (moderate negative)

Signal:(42.86) Neutral

Tempest Therapeutics, Korrelasjon

10 Mest positive korrelasjoner
SIFY	0.842
SVOK	0.816
FORE	0.814

10 Mest negative korrelasjoner
RAVN	-0.856

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Tempest Therapeutics, Korrelasjon - Valuta/Råvare

0.59
( weak )

0.56
( weak )

0.00
( neutral )

0.32
( neutral )

Tempest Therapeutics, Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-381 000 (0.00 %)
EPS:	$-1.910

FY	2023
Omsetning:	$0
Bruttogevinst:	$-381 000 (0.00 %)
EPS:	$-1.910

FY	2022
Omsetning:	$0
Bruttogevinst:	$-1.81M (0.00 %)
EPS:	$-3.18

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-4.27

Financial Reports:

No articles found.

Tempest Therapeutics,

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.